GSK’s $2.5B Plan to Speed Up Drug Development | Business and Finance News

GSK just unveiled a bold $2.5 billion cost-cutting plan to turbocharge late-stage drug development, fueling investor confidence and accelerating innovation—especially as CEO Luke Miels pushes aggressive growth through acquisitions and R&D, aiming to hit £40 billion in revenue by 2031 while reinvesting £400 million back into the UK. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e6e485a036df65a9